Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 58.74 USD -0.07% Market Closed
Market Cap: 119.1B USD
Have any thoughts about
Bristol-Myers Squibb Co?
Write Note

Bristol-Myers Squibb Co
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bristol-Myers Squibb Co
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Bristol-Myers Squibb Co
NYSE:BMY
Cash Paid for Dividends
-$4.8B
CAGR 3-Years
-4%
CAGR 5-Years
-13%
CAGR 10-Years
-7%
Johnson & Johnson
NYSE:JNJ
Cash Paid for Dividends
-$11.7B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-4%
Pfizer Inc
NYSE:PFE
Cash Paid for Dividends
-$9.4B
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Cash Paid for Dividends
-$7.7B
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Zoetis Inc
NYSE:ZTS
Cash Paid for Dividends
-$764m
CAGR 3-Years
-19%
CAGR 5-Years
-21%
CAGR 10-Years
-18%
Eli Lilly and Co
NYSE:LLY
Cash Paid for Dividends
-$4.5B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-8%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Market Cap
119.1B USD
Industry
Pharmaceuticals
Economic Moat
None

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company renowned for its innovative approach to discovering and developing transformative medicines. Founded over 160 years ago, BMS has built a robust portfolio that includes therapies across oncology, immunology, cardiovascular disease, and infectious diseases, focusing on addressing unmet medical needs. The company is celebrated for its substantial investments in research and development, which have led to groundbreaking treatments like Opdivo and Eliquis. These products have not only propelled revenue growth but also established BMS as a key player in the life sciences sector, showcasing its commitment to advancing the health and well-being of patients around the world. For investors, BMS presents a compelling opportunity rooted in a strong pipeline and strategic partnerships. The company has navigated recent challenges, including patent expirations, by fostering innovation and expanding its therapeutic offerings through mergers and acquisitions. In the ever-evolving healthcare landscape, BMS aims to leverage its scientific expertise and market presence to drive sustainable growth. With a focus on maintaining a balanced portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb stands out as a resilient entity poised to deliver long-term value, supported by a robust pipeline expected to bring additional blockbuster products to market in the coming years.

BMY Intrinsic Value
72.12 USD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Bristol-Myers Squibb Co's Cash Paid for Dividends?
Cash Paid for Dividends
-4.8B USD

Based on the financial report for Sep 30, 2024, Bristol-Myers Squibb Co's Cash Paid for Dividends amounts to -4.8B USD.

What is Bristol-Myers Squibb Co's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-7%

Over the last year, the Cash Paid for Dividends growth was -2%. The average annual Cash Paid for Dividends growth rates for Bristol-Myers Squibb Co have been -4% over the past three years , -13% over the past five years , and -7% over the past ten years .

Back to Top